146 related articles for article (PubMed ID: 37072487)
21. The Application and Comparison of Machine Learning Models for the Prediction of Breast Cancer Prognosis: Retrospective Cohort Study.
Xiao J; Mo M; Wang Z; Zhou C; Shen J; Yuan J; He Y; Zheng Y
JMIR Med Inform; 2022 Feb; 10(2):e33440. PubMed ID: 35179504
[TBL] [Abstract][Full Text] [Related]
22. Prognosis prediction of extremity and trunk wall soft-tissue sarcomas treated with surgical resection with radiomic analysis based on random survival forest.
Yang Y; Ma X; Wang Y; Ding X
Updates Surg; 2022 Feb; 74(1):355-365. PubMed ID: 34003477
[TBL] [Abstract][Full Text] [Related]
23. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy.
Zhenhao Z; Xiaofeng C; Hao J; Ming Y; Hongtao Z; Wenrui H; Cheng Z; Xiaochen Z; Gongxian W
Cancer Med; 2022 Sep; 11(17):3251-3259. PubMed ID: 35307955
[TBL] [Abstract][Full Text] [Related]
24. Prediction of prognosis in elderly patients with sepsis based on machine learning (random survival forest).
Zhang L; Huang T; Xu F; Li S; Zheng S; Lyu J; Yin H
BMC Emerg Med; 2022 Feb; 22(1):26. PubMed ID: 35148680
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
Shimodaira K; Nakashima J; Nakagami Y; Hirasawa Y; Hashimoto T; Satake N; Gondo T; Namiki K; Ohori M; Ohno Y
Urol J; 2020 Jan; 17(1):42-49. PubMed ID: 30882158
[TBL] [Abstract][Full Text] [Related]
26.
Rezk M; Chandra A; Addis D; Møller H; Youssef M; Dasgupta P; Yamamoto H
BMJ Open; 2019 Mar; 9(3):e025161. PubMed ID: 30852544
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
28. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
29. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract][Full Text] [Related]
30. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
[TBL] [Abstract][Full Text] [Related]
31. Pilot study of an artificial intelligence-based deep learning algorithm to predict time to castration-resistant prostate cancer for metastatic hormone-naïve prostate cancer.
Nakata W; Mori H; Tsujimura G; Tsujimoto Y; Gotoh T; Tsujihata M
Jpn J Clin Oncol; 2022 Sep; 52(9):1062-1066. PubMed ID: 35750041
[TBL] [Abstract][Full Text] [Related]
32. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.
Yamaguchi Y; Hayashi Y; Ishizuya Y; Takeda K; Nakai Y; Arai Y; Nakayama M; Kakimoto K; Nishimura K
Jpn J Clin Oncol; 2015 Feb; 45(2):197-201. PubMed ID: 25381383
[TBL] [Abstract][Full Text] [Related]
33. Machine-Learning Models for Multicenter Prostate Cancer Treatment Plans.
Syed K; Sleeman W; Soni P; Hagan M; Palta J; Kapoor R; Ghosh P
J Comput Biol; 2021 Feb; 28(2):166-184. PubMed ID: 32985908
[TBL] [Abstract][Full Text] [Related]
34. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer.
Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
Sci Rep; 2019 Aug; 9(1):12071. PubMed ID: 31427687
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Kimura S; Parizi MK; Enikeev DV; Glybochko PV; Seebacher V; Fajkovic H; Mostafaei H; Lysenko I; Janisch F; Egawa S; Shariat SF
Clin Genitourin Cancer; 2019 Dec; 17(6):409-418. PubMed ID: 31558410
[TBL] [Abstract][Full Text] [Related]
37. Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.
Fallara G; Belladelli F; Robesti D; Raggi D; Nocera L; Marandino L; Galsky MD; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
Crit Rev Oncol Hematol; 2022 Nov; 179():103801. PubMed ID: 36031173
[TBL] [Abstract][Full Text] [Related]
38. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
Chikamatsu S; Shiota M; Onozawa M; Hinotsu S; Kitagawa Y; Sakamoto S; Kawai T; Eto M; Kume H; Akaza H;
Int J Urol; 2021 Sep; 28(9):927-935. PubMed ID: 34028097
[TBL] [Abstract][Full Text] [Related]
40. Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
Afriansyah A; Hamid ARA; Mochtar CA; Umbas R
Int J Urol; 2019 Jan; 26(1):83-89. PubMed ID: 30269369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]